Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?

The article describes the possible pathophysiological origin of COVID-19 and the crucial role of renin-angiotensin system (RAS), providing several “converging” evidence in support of this hypothesis. SARS-CoV-2 has been shown to initially upregulate ACE2 systemic activity (early phase), which can su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in biological regulation 2021-08, Vol.81, p.100820-100820, Article 100820
Hauptverfasser:	Montanari, Mariele, Canonico, Barbara, Nordi, Evelyn, Vandini, Daniela, Barocci, Simone, Benedetti, Serena, Carlotti, Eugenio, Zamai, Loris
Format:	Artikel
Sprache:	eng
Schlagworte:	ACE2 ADAM17 ADAM17 Protein - antagonists & inhibitors ADAM17 Protein - biosynthesis Angiotensin Angiotensin I - metabolism Angiotensin-converting enzyme 2 Angiotensin-Converting Enzyme 2 - antagonists & inhibitors Angiotensin-Converting Enzyme 2 - biosynthesis Coronaviruses COVID-19 COVID-19 - metabolism COVID-19 Drug Treatment Endocrine system Enzymes Gene Expression Regulation, Enzymologic Humans Hyperactivity Hypertension Hypotheses Inflammation Peptide Fragments - metabolism Peptides Positive feedback RAS inhibitors Renin Renin-Angiotensin System SARS-CoV-2 - metabolism Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - antagonists & inhibitors Spike Glycoprotein, Coronavirus - metabolism Spike N-Terminal domain Thromboembolism Thrombosis Up-Regulation Vaccines Viral diseases Zinc-chelating agents Zinc-metalloproteases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!